Longqin Hu

20PUBLICATIONS
15CO-AUTHORS
Regenerative medicine (incl. stem cells)Medical devicesCardiology (incl. cardiovascular diseases)Pharmaceutical delivery technologiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Nov 02, 2026
Remibrutinib (Rhapsido®), a covalent Bruton's tyrosine kinase inhibitor approved for chronic spontaneous urticaria.

|Oct 01, 2026
Vepdegestrant: the first FDA-approved oral PROTAC and a milestone in targeted protein degradation.

|Sep 29, 2026
Baxdrostat (Baxfendy®), a first-in-class aldosterone synthase inhibitor approved for adults with uncontrolled hypertension.

|Aug 25, 2026
Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD).

|Aug 18, 2026
Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer.

|Aug 07, 2026
From propofol to cipepofol (Cypsedo®), a new intravenous general anesthetic approved for adults undergoing surgery.

Pageof 4

Frequent Collaborators

5 joint publications

Jeffrey Yang

5 joint publications

Michael D Ward

5 joint publications

Ahmed R Ali

2 joint publications

Sumi Lee